Press Releases

Manhattan Scientifics Announces Successful Completion of its Affiliate Imagion Biosystems IPO

(June 22, 2017) Manhattan Scientifics Inc. (MHTX), Imagion Biosystems (IBX) and the National Institute of Health (NIH) collectively have invested over $20M to develop and commercialize the cancer diagnostic nanotechnology originally developed by Dr. Flynn. Full release

Manhattan Scientifics Schedules Investor Conference Call on Its Affiliate, Imagion Biosystems IPO

(June 14, 2017) Manhattan Scientifics Inc. announced today that it will host a conference call for MHTX investors at 12:00 pm Eastern Time on Friday, June 16, 2017 to provide an update and briefing on the pending Imagion Biosystems IPO (IBX). There will not be a Q&A Session and participants will be restricted to listening mode. Full release

Manhattan Scientifics Affiliate Files for Initial Public Offering on Australian Stock Exchange

(June 1, 2017) Manhattan Scientifics Inc. is pleased to announce that its affiliate company, Imagion Biosystems Limited (“Imagion”), formerly known as Senior Scientific, LLC, filed a prospectus with the Australian Securities and Investment Commission and applied to the Australian Securities Exchange for an Initial Public Offering ("IPO") to raise up to A$12 million at A$0.20 per share. Full release

Manhattan Scientifics Announces Retirement of Long-Term Debt

(February 14, 2017) NEW YORK--Manhattan Scientifics Inc. announced the retirement of $2.5 million in current debt. The company said it now has a virtually debt-free balance sheet. Full release

MHTX Announces Retirement of its Current $2.5M Long Term Debt

(February 13, 2017) NEW YORK--Manhattan Scientifics Inc. announced today that equity capital to retire $2.0M of the $2.5M debt was raised by Manhattan Scientifics' subsidiary, Imagion Biosystems. Full release

Manhattan Scientifics Cancer Diagnostic IPO Update

(December 19, 2016) Manhattan Scientifics Inc. anticipates positive changes resulting from its plan to list the company’s cancer diagnostic unit, Senior Scientific, on the Australian Stock Exchange. Full release

Manhattan Scientifics Announces Agreement to Spin-Off and IPO its Senior Scientific Unit

(November 29, 2016) NEW YORK--Manhattan Scientifics (OTCQB:MHTX) announces that it is implementing a plan to have Senior Scientific, the company’s cancer diagnostic unit, pursue an IPO and listing on the Australian Stock Exchange (ASX) (see description at end of release). Full release

Manhattan Scientifics Signs Development Agreement with General Cable

(July 25, 2016) NEW YORK--Manhattan Scientifics, Inc. (OTCQB:MHTX) announced today that it has signed a $500,000 Joint Development Agreement with General Cable (NYSE: BGC). Full release

Ex-GE Healthcare CTO Michael J. Harsh Joins Manhattan Scientifics Advisory Board

(March 29, 2016) NEW YORK--Manhattan Scientifics, Inc. announced today that Michael J. Harsh, former VP & Chief Technology Officer for GE Healthcare and a recognized global expert on medical imaging technology, has joined the Company’s Science and Technology Advisory Board. Full release

Senior Scientific and Weill Cornell Medicine to Pursue Non-Invasive Prostate Cancer Detection

(February 16, 2016) NEW YORK -- Manhattan Scientifics, Inc. announced today that its wholly-owned subsidiary Senior Scientific, LLC, which is developing a platform for the early detection of cancer and other human diseases, has established a research collaboration with Weill Cornell Medicine. Full release

Senior Scientific Teams Up With University of Michigan On In Vivo Breast Cancer Diagnostic

(January 13, 2016) Manhattan Scientifics, Inc. announced today that its Senior Scientific unit, developing a platform for the early detection of cancer and other human diseases, has established a Research Collaboration with The University of Michigan Medical School. Full release

Senior Scientific Extends Collaboration with MD Anderson Cancer Center

(December 14, 2015) Manhattan Scientifics, Inc. announced today that its Senior Scientific, LLC unit, developing a platform for the early detection of cancer and other human diseases, has renewed its Collaboration Agreement with The University of Texas MD Anderson Cancer Center, establishing a multi-year program with extended scope. Full release

MHTX Announces Chinese Patent Issued for the Early Cancer Detection Technology Platform

(October 26, 2015) ALBUQUERQUE, N.M.--Senior Scientific, LLC, a unit of Manhattan Scientifics (MHTX: OTCQB) and a developer of nanobiotechnology for the early detection and localization of cancer and other human diseases, today announced that the Company has recently been granted a patent by the Chinese Patent Office. Full release

Manhattan Scientifics, Inc. Announces Stock Repurchase Program

(August 26, 2015) NEW YORK--Manhattan Scientifics, Inc. ("Manhattan Scientifics”), (OTCQB:MHTX) announced that it is initiating a share repurchase program. Manhattan Scientifics' Board of Directors designated a program to repurchase, from time to time, at management's discretion, shares of the Company's common stock with a value of up to $500,000 in the open market at prevailing market prices over the next 12 months. Full release

MHTX Announces Issuance of Additional Patent Covering Detection and Imaging of Cancer Cells

(August 10, 2015) NEW YORK--Manhattan Scientifics, Inc. announced today that its Senior Scientific, LLC unit, a nanobiotechnology company for the early detection and localization of cancer and other human diseases, has been granted an additional United States Patent for its MRX™ cancer detection technology. Full release

Manhattan Scientifics Engages Services of Torreya Partners

(July 16, 2015) NEW YORK--Manhattan Scientifics, Inc. today announced the engagement of Torreya Partners and its professional services sister company, Torreya Insights. Full release

A Letter from the New President of Senior Scientific LLC

(May 7, 2015) Cancer continues to be one of the leading causes of mortality globally. Despite technical advances in science and medicine made in the last 150 years we still lack effective forms of therapy for many types of cancer, and the general consensus within the medical community is that more lives could be saved if cancer could be detected earlier. Full release

Letter to Shareholders

(April 20, 2015) Manhattan Scientifics, Inc. owns and is commercializing two nanotechnology businesses: nanostructured metals through our Metallicum subsidiary, and nanotechnology for the very early detection of cancers through our Senior Scientific subsidiary. The past year has been an important one for Manhattan Scientifics with a number of notable achievements. Full release

Manhattan Scientifics Announces Return of Marvin Maslow as Chairman of the Board

(March 25, 2015) NEW YORK--Manhattan Scientifics, Inc. announced today that Marvin Maslow, founder of MSI, has re-joined the Company’s Board of Directors as Chairman. Full release

MHTX to Immediately Receive $8M as it Reacquires its Nano-Structured Metals Tech & Related IP

(February 18, 2015) NEW YORK--Manhattan Scientifics, Inc. has reacquired all rights in its nano-structured metals technology from its former Licensee whose strategic corporate priorities had changed. The agreement includes a one-time payment to Manhattan of $8 million, the assignment to Manhattan of all related IP and the transfer of ownership of various ECAP machinery and equipment used in the manufacturing process of nano-structured metals. Full release

MHTX Recruits Robert R. Proulx as New President and COO for Its Senior Scientific Subsidiary

(January 14, 2015) ALBUQUERQUE, N.M.--Manhattan Scientifics, Inc. has recruited Robert R. Proulx (pronounced “Pru”) to the position of President and Chief Operating Officer of its Senior Scientific LLC subsidiary, effective January 12. Full release

Manhattan Scientifics Announces Expansion of Executive Team at Its Senior Scientific Subsidiary

(December 30, 2014) ALBUQUERQUE, N.M.--Manhattan Scientifics, Inc. is recruiting a seasoned executive to oversee Senior Scientific’s next stage of product development for its MRX diagnostic technology for the early detection of cancer. Full release

Manhattan Scientifics Completes $2.0 Million Equity Raise

(November 21, 2014) ALBUQUERQUE, N.M.--Manhattan Scientifics, Inc. has completed a $2.0 million equity raise. Details of the raise are available in the Company’s November 18th 8K filing with the SEC. The proceeds will primarily be used to fund the advancement, demonstration and validation of its MRX cancer diagnostic technology under development by its subsidiary, Senior Scientific, LLC. Full release

MHTX’s Unparalleled Cancer Measurement Technology Featured in MD Anderson Presentation

(October 8, 2014) ALBUQUERQUE, N.M.--Senior Scientific LLC, a subsidiary of Manhattan Scientifics, Inc. (OTCQB: MHTX), is currently collaborating with The University of Texas MD Anderson Cancer Center (MDACC) to advance, demonstrate and validate a cancer detection and measurement technology originally developed by Edward R. Flynn, PhD. John D. Hazle, PhD of the MD Anderson Cancer Center. Full release

Past Releases